OA12778A - Pharmaceutical combination of COX-2 inhibitors andipiates. - Google Patents

Pharmaceutical combination of COX-2 inhibitors andipiates. Download PDF

Info

Publication number
OA12778A
OA12778A OA1200400220A OA1200400220A OA12778A OA 12778 A OA12778 A OA 12778A OA 1200400220 A OA1200400220 A OA 1200400220A OA 1200400220 A OA1200400220 A OA 1200400220A OA 12778 A OA12778 A OA 12778A
Authority
OA
OAPI
Prior art keywords
combination
daim
codeine
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Application number
OA1200400220A
Other languages
English (en)
Inventor
Michael Christian Norris
Original Assignee
Adcock Ingram Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adcock Ingram Ltd filed Critical Adcock Ingram Ltd
Publication of OA12778A publication Critical patent/OA12778A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200400220A 2002-02-19 2003-02-14 Pharmaceutical combination of COX-2 inhibitors andipiates. OA12778A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA200201395 2002-02-19

Publications (1)

Publication Number Publication Date
OA12778A true OA12778A (en) 2006-07-06

Family

ID=27758232

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400220A OA12778A (en) 2002-02-19 2003-02-14 Pharmaceutical combination of COX-2 inhibitors andipiates.

Country Status (20)

Country Link
US (1) US20050090517A1 (hr)
EP (2) EP2050453B1 (hr)
JP (1) JP2005519936A (hr)
CN (1) CN100418533C (hr)
AP (1) AP1862A (hr)
AT (2) ATE524186T1 (hr)
AU (1) AU2003208485B2 (hr)
CA (1) CA2476939C (hr)
CY (1) CY1108839T1 (hr)
DE (1) DE60325020D1 (hr)
DK (1) DK1478366T3 (hr)
EG (1) EG24845A (hr)
ES (2) ES2376500T3 (hr)
IL (2) IL163637A0 (hr)
NZ (1) NZ535500A (hr)
OA (1) OA12778A (hr)
PT (2) PT1478366E (hr)
SI (1) SI1478366T1 (hr)
WO (1) WO2003070251A1 (hr)
ZA (1) ZA200407485B (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530620A (ja) * 2004-04-01 2007-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカムを含む組成物
JP2008501655A (ja) * 2004-06-04 2008-01-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング メロキシカム含有組成物
ITMI20060983A1 (it) * 2006-05-18 2007-11-19 Formevet S P A Composizioni farmaceutiche veterinarie per il trattamento del dolore e dell'inifiamazione
WO2007138466A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Pharmaceutical compositions comprising meloxicam and tramadol combination
US20080026054A1 (en) * 2007-04-27 2008-01-31 Nectid Inc. Novel anelgesic combination
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2311446A1 (en) 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
IT1398321B1 (it) * 2010-02-26 2013-02-22 Formevet Spa Ora Formevet Srl Associazione tra un analgesico ad azione centrale e un antinfiammatorio inibitore selettivo della cicloossigenasi 2 per il trattamento dell'infiammazione e del dolore in campo veterinario
EP2392319A1 (en) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions of co-crystals of tramadol and coxibs
WO2015004505A1 (es) * 2013-07-11 2015-01-15 More Pharma Corporation, S. De R.L. De C.V. Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
US20210346328A1 (en) * 2018-09-21 2021-11-11 The Johns Hopkins University Compositions and methods for treating metabolic disorders
CN115300515A (zh) * 2022-08-11 2022-11-08 南京红地生物科技有限公司 一种含有美洛昔康和盐酸曲马多的长效注射液

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA845785B (en) * 1983-06-10 1985-03-27 Adcock Ingram Lab Ltd Pharmaceutical unit
ZA893422B (en) * 1988-02-24 1991-01-30 Adcock Ingram Lab Ltd Pharmaceutical composition
AU3990895A (en) * 1995-12-05 1997-06-27 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
FR2770131A1 (fr) * 1997-10-27 1999-04-30 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AU773642C (en) * 1997-12-22 2006-04-06 Mundipharma Pty Limited Opioid agonist/antagonist combinations
EP1289558A2 (en) * 2000-05-31 2003-03-12 Warner-Lambert Company Llc Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
CN100588395C (zh) * 2000-06-13 2010-02-10 Wyeth公司 含有环氧化酶-2抑制剂的止痛和抗炎药物

Also Published As

Publication number Publication date
EP1478366B1 (en) 2008-12-03
CY1108839T1 (el) 2014-07-02
EP2050453A1 (en) 2009-04-22
NZ535500A (en) 2006-09-29
IL163637A (en) 2010-11-30
ES2318113T3 (es) 2009-05-01
CA2476939A1 (en) 2003-08-28
IL163637A0 (en) 2005-12-18
ES2376500T3 (es) 2012-03-14
CN100418533C (zh) 2008-09-17
EG24845A (en) 2010-10-21
AU2003208485B2 (en) 2009-05-28
AU2003208485A1 (en) 2003-09-09
PT1478366E (pt) 2009-03-10
JP2005519936A (ja) 2005-07-07
ATE524186T1 (de) 2011-09-15
ATE415971T1 (de) 2008-12-15
ZA200407485B (en) 2005-12-28
EP1478366A1 (en) 2004-11-24
SI1478366T1 (sl) 2009-06-30
US20050090517A1 (en) 2005-04-28
DK1478366T3 (da) 2009-03-30
CN1646133A (zh) 2005-07-27
WO2003070251A1 (en) 2003-08-28
AP1862A (en) 2008-07-07
PT2050453E (pt) 2012-01-03
EP2050453B1 (en) 2011-09-14
AP2004003134A0 (en) 2004-09-30
DE60325020D1 (de) 2009-01-15
CA2476939C (en) 2012-08-28

Similar Documents

Publication Publication Date Title
OA12778A (en) Pharmaceutical combination of COX-2 inhibitors andipiates.
Lázaro-Ibáñez et al. Participation of the nitric oxide–cyclic GMP–ATP-sensitive K+ channel pathway in the antinociceptive action of ketorolac
Löscher Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy
Keyhanfar et al. Evaluation of antinociceptive effect of pregabalin in mice and its combination with tramadol using tail flick test
Abbott et al. Phenacetin, acetaminophen and dipyrone: analgesic and rewarding effects
Onuţu Duloxetine, an antidepressant with analgesic properties–a preliminary analysis
Rasmussen Treatment of elevated intracranial pressure with indomethacin: friend or foe?
Moreno-Rocha et al. Antinociceptive effects of tramadol in co-administration with metamizol after single and repeated administrations in rats
García-Hernández et al. Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat
Granados-Soto et al. A review of the pharmacokinetic and pharmacodynamic factors in the potentiation of the antinociceptive effect of nonsteroidal anti-inflammatory drugs by caffeine
Sartini et al. Open experience with a new myorelaxant agent for low back pain
Brown-Croyts et al. Phenobarbital pre-treatment prevents kainic acid-induced impairments in acquisition learning
BR0317950A (pt) Inibidores de quinurrenina 3-hidroxilase para o tratamento de diabetes por aumento do número de ilhotas de células de langerhans
Kelkar et al. Urticaria and angioedema from cyclooxygenase-2 inhibitors.
Luo et al. Effects of three different Ca2+ pump ATPase inhibitors on evoked contractions in rabbit aorta and activities of Ca2+ pump ATPases in porcine aorta
Saini et al. Fixed drug eruptions: causing drugs, pattern of distribution and causality assessment in a leading tertiary care hospital
Salinska et al. Dantrolene antagonizes the glycineB site of the NMDA receptor
Fruhwald et al. Differential reversal of drug-induced small bowel paralysis by cerulein and neostigmine
Mitchell et al. Antihypernociceptive synergy between ibuprofen, paracetamol and codeine in rats
Alzarea et al. The effect of an α-7 nicotinic allosteric modulator PNU120596 and NMDA receptor antagonist memantine on depressivelike behavior induced by LPS in mice: The involvement of brain microglia†. Brain Sci. 2022; 12: 11
Kardani et al. Cycloserine-induced Acute Psychiatric Episode with XDRTB treatment in an Indian Patient-A Report.
Putri et al. Mechanism of Action, Cellular Targets and Clinical Importance of Analgesic Therapy in Postoperative Pediatric Patients: A Brief Observation
Déciga-Campos et al. Participation of the NO-cyclic GMP pathway in rofecoxib-induced antinociception
Jesuthasan et al. Pain Analgesic Developments in the Genomic Era
Mogole et al. The management of muscle pain